Related references
Note: Only part of the references are listed.Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: A systematic review and meta-analysis
Harrison H. Lee et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus
Jonathan Silverberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Prevalence and Severity of Itching in Patients with End-Stage Renal Disease: Treatment with Nalfurafine Hydrochloride
Hidetomo Nakamoto et al.
BLOOD PURIFICATION (2019)
Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody
Sohei Oyama et al.
EXPERIMENTAL DERMATOLOGY (2018)
Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study
Kenji Kabashima et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Prognostic importance and determinants of uremic pruritus in patients receiving peritoneal dialysis: A prospective cohort study
Hon-Yen Wu et al.
PLOS ONE (2018)
Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Thomas Ruzicka et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association of uremic pruritus in hemodialysis patients with the number of days of high mean 24-hour particulate matter with a diameter of <2.5 μm
Ming-Hui Liu et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2017)
International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis
Hugh C. Rayner et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Interleukin 31 and skin diseases: A systematic review
Sebastiano Gangemi et al.
ALLERGY AND ASTHMA PROCEEDINGS (2017)
Treatment of Uremic Pruritus: A Systematic Review
Elizabeth Simonsen et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2017)
The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study
O. Nemoto et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016
Hidehisa Saeki et al.
JOURNAL OF DERMATOLOGY (2016)
Comparative Cut-off Value Setting of Pruritus Intensity in Visual Analogue Scale and Verbal Rating Scale
Makiko Kido-Nakahara et al.
ACTA DERMATO-VENEREOLOGICA (2015)
Placebo Effects on Itch: A Meta-Analysis of Clinical Trials of Patients with Dermatological Conditions
Antoinette I. M. van Laarhoven et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Nalfurafine hydrochloride to treat pruritus: a review
Shigeki Inui
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2015)
Pruritus in hemodialysis patients: Results from the Japanese Dialysis Outcomes and Practice Patterns Study (JDOPPS)
Naoki Kimata et al.
HEMODIALYSIS INTERNATIONAL (2014)
Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis
Mei-Ju Ko et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Visual Analogue Scale: Evaluation of the Instrument for the Assessment of Pruritus
Adam Reich et al.
ACTA DERMATO-VENEREOLOGICA (2012)
The 5-D itch scale: a new measure of pruritus
S. Elman et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study
Hiroo Kumagai et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Share Paper
